KNSA (Kiniksa Pharmaceuticals International) Total Current Assets: $594.2 Mil (As of Mar. 2026)


KNSA Kiniksa Pharmaceuticals International PLC KNSA
54 GF Score
Price $64.08
GF Value $48.15
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Total Current Assets?

Kiniksa Pharmaceuticals International KNSA +1.91% 54 Total Current Assets is $594.2 Mil as of Mar. 2026. GuruFocus rates KNSA with a GF Score™ of 54/100 and a GF Value™ of $48.15 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Kiniksa Pharmaceuticals International's total current assets for the quarter that ended in Mar. 2026 was $594.2 Mil.

Kiniksa Pharmaceuticals International  (NAS:KNSA) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Kiniksa Pharmaceuticals International's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=468.093-219.593+0.75 * 23.224+0.5 * 73.141
=302.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiniksa Pharmaceuticals International Total Current Assets Related Terms

Kiniksa Pharmaceuticals International Total Current Assets Historical Data

* Premium members only.

The historical data trend for Kiniksa Pharmaceuticals International's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiniksa Pharmaceuticals International Total Current Assets Chart

Kiniksa Pharmaceuticals International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 196.45 243.06 276.30 331.80 527.18

Kiniksa Pharmaceuticals International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 355.91 420.31 475.53 527.18 594.17
KNSA
54GF Score
Kiniksa Pharmaceuticals International PLC KNSA
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiniksa Pharmaceuticals International Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Kiniksa Pharmaceuticals International's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=414.074+15.594+54.895+42.614
=527.2

Kiniksa Pharmaceuticals International's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=468.093+23.224+73.141+29.714
=594.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of $594.2 Mil mean?
Kiniksa Pharmaceuticals International (KNSA) has a Total Current Assets of $594.2 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Kiniksa Pharmaceuticals International and its competitors.
Is Kiniksa Pharmaceuticals International's Total Current Assets too high?
Kiniksa Pharmaceuticals International's current Total Current Assets is $594.2 Mil. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Total Current Assets compare to INDV and AMRX?
Kiniksa Pharmaceuticals International's Total Current Assets of $594.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Drug Manufacturers company?
A good Total Current Assets depends on the Drug Manufacturers industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Kiniksa Pharmaceuticals International and its competitors. Kiniksa Pharmaceuticals International's current Total Current Assets is $594.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $48.15, compared to a current price of $64.08 — trading 33.1% above its estimated fair value. The current Total Current Assets is $594.2 Mil. Kiniksa Pharmaceuticals International's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current Total Current Assets is $594.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of $64.08 is trading 33.1% above its estimated GF Value™ of $48.15. GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.

Key valuation signals for KNSA:

  • Total Current Assets: $594.2 Mil
  • GF Value™: $48.15 vs. price of $64.08 (33.1% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
54GF Score

Get the complete analysis for KNSA

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$64.08
Price
$48.15
GF Value